Researchers from the University of Dresden have usedembryonic stem cells to grow an intact spinal cord in a petri dish, the team reported this week. Its an enormous achievement in a field that has long viewed neural tissue as the ultimate challenge, and one which could give hope to millions of people suffering fromspinal cord injuries.

Neurons, the cells that form the thinking matrix of your brain and carry its orders to the rest of your body, are very difficult to grow. For a long time growing neurons was thought to be impossible, but then it was discovered that olfactory neurons regrow. This is why you can lose your sense of smell for a few days then slowly regain it; the neuron ends, basically open-ended synapses facing into your nasal cavity, areburned away by corrosive smells, butslowly growback. Intense study followed this discovery, as scientists tried to track down how our olfactory neurons regrow, and others packed them directly into severed spinal cords with real success. In the image above, olfactory neurons have granted a lab rat regains some ability to walk again after being paralyzed (though to be fair, those same researchers are the ones who paralyzed it).

Even if you can grow one, the spinal cord still needs to form connections with an incredible number of body parts.

Now, rather than trying toforceour spinal neurons to act like nasalones, this German teammay have a way of making new ones from scratch. Certain diseases and massive injuries could easily render a spine beyond all hope of repair, but in such a situation a full replacement might still work. Remember, though, that one of the reasons neurons are hard to work with is that they must form complex synaptic connections with other neurons to work properly; just growing the spinal cord is only half the battle, and the patients body still has to accept the new routing hardware and integrate it properly.Still, even just the ability to closelyobserve the growth ofa full spinal cord could move neuronal research forward by leaps and bounds.

This technique worked essentially by letting the stem cells go to work and getting as far out of the way as possible; rather than introducing some novel new growth factor, the researchers basically just created an environment where the spine could grow just like it would in a body. Their setup involved inserting small bubbles of stem cells into a nutrient-rich growth mediumand letting them go from there.Given all the opportunities they required, the cells naturally started coordinating andshuntinggrowth factors around most notably the trio of hedgehog signaling molecules.

The teams diagram shows inserted ESC colonies growing into larger cysts which eventually associate.

The most famous of the three-member band, both for its name and its function, is Sonic Hedgehog, which can stimulate directed neuron growth through itsconcentration gradient. A high concentration of Sonic Hedgehog leads the cord to growmotor neurons tocarry the brains muscular commands, while a lower concentration near the top of the cord will lead to interneurons that wire up the spine itself. This is roughly analogous to growth factors in trees, where the widen the trunk molecule is made at the bottom and ferried up, and the split the trunk into branches molecule is made at the top and ferried down; the two opposing concentration gradients lead to the tree-shaped trees we all know so well, with branches becoming less common toward the bottom, where trunk-width takes priority.

In this case, the stem cells and spinal cord were froma mouse, which allowed for lower cost and ethical considerations, butthe principles of growth and signaling should bethe same. This technique made use of embryonic stem cells (ESCs), which in humans must be collected from fertility clinics and similar, but the ultimate human progenitor cell might not be necessary to further research. As scientists come to understand the mechanics of this breakthrough better, and replicate its results a few more times, it would presumably become possible to begin thisprocesswithinduced stem cells made from adult tissue. If not, this will remain an interesting research tool with little real-world applicabilitydue to the costs and regulatory problemswith ESCs.

Star Trek had a spinal transplant episode but even in the 24th century, its an experimental procedure.

Lab-grown organs are coming far, fast. Somewhere in the world today there are gel baths and petri dishes growing human bladders, eyes, and penises, esophagi, livers, and breasts. Even the quest for lab grown meatfalls under the same basic research umbrella, as scientists use similartechniques to create high quality chicken andbovine skeletal muscle. As with this spinal cord, each of these areas of research is trying to create laboratory conditions that perfectly mimic the body, so cells grow and develop normally.

See the original post here:
Spinal cord has successfully been grown in a lab

Author: Ian Murnaghan BSc (hons), MSc - Updated: 11 September 2014 | Comment

A bone marrow stem cell transplant uses stem cells derived from bone marrow to provide a fresh and healthy source of new blood cells which in turn, allows for a patient to receive higher doses of chemotherapy to treat certain types of cancer such as leukaemia. This ultimately means that a person has a better chance of surviving cancer. The bone marrow stem cells may be allogeneic and therefore donated by a family member of stranger, or they may be autologous, which utilizes a patient's own stem cells.

Bone marrow stem cells are found in bone marrow and in a person's blood. After stem cells multiply, they form immature blood cells, which are then subject to a collection of changes that allow them to develop into mature blood cells. Once mature, the blood cells migrate from the marrow and are introduced into the bloodstream, where they provide important functions in keeping the body alive and healthy.

A patient will usually receive some chemotherapy to reduce cancer cells before stem cells are collected. The harvested stem cells are also treated to ensure that no cancer cells remain. Higher doses of chemotherapy are then given, sometimes alongside complete body radiation, to confirm that no cancer remains. Stem cells are then transplanted back into the body via a rapid injection. Stem cells will eventually migrate to the bone marrow, where they latch onto other cells there and develop into the different blood cells.

Stem cells are then infused into the patient via an intravenous line over several hours. Stem cells travel to the patient's bone marrow where they develop and produce the blood cells necessary for blood functioning. Patients may also still be given drug therapy for some time to reduce the chances of immune rejection.

Bone marrow stem cell harvests are clearly a life saving technique for those suffering from certain cancers such as leukaemia. They are one of the 'older' stem cell therapies and have been proven effective for decades now. There are, however, still issues of rejection that warrant further development and refinement of stem cell harvesting techniques. It is hoped that scientists will continue to focus on research to improve the odds of success for this important treatment.

You might also like...

Leave a Comment, Ask for Advice or Share Your Story...

Sohaila Reda - 9-Aug-14 @ 5:06 PM

Continue reading here:
Bone Marrow Stem Cell Harvest

Stem Cells Enhancement Naturally!
How to Enhance Your Bone Marrow Stem Cells.

By: Dave W Easter

See the original post here:
Stem Cells Enhancement Naturally! - Video

Researchers found stem cells in mouse nails that performed two roles They cause nails to grow, and focus on repair when it is lost or injured The experts tracked how stem cells in the nails of mice split and grow It is hoped the same cells could be manipulated to grow tissue in other body parts

By Ellie Zolfagharifard for MailOnline

Published: 10:23 EST, 24 November 2014 | Updated: 10:23 EST, 24 November 2014

The blue-tailed skink has the remarkable ability to lose its tail to distract predators, and then grow a new one.

And someday, thanks to cells found in our nails, humans could have similar lizard-like abilities that will help us regrow lost limbs.

Researchers in the US recently found unique stem cells in nails that perform two roles - they cause nails to grow, and they focus on nail repair when it is lost or injured.

Researchers in the US recently found unique stem cells (shown in the above animation) in nails that perform two roles; they cause nails to grow, and focus on nail repair when it is lost or injured

The researchers claim these stem cells could be manipulated to grow tissue for other body parts, helping to someday recover lost limbs or organs.

The elusive stem cells were found at the University of Southern California by attaching dyes as 'labels' on mouse nail cells.

Many of these cells repeatedly divided, diluting the dyes and labels in the process.

See the rest here:
Could nails help us regrow LIMBS? Stem cells found on fingers and toes could someday give humans lizard-like abilities

Scientists have created pain in a dish by converting skin cells into sensitive neurons.

The laboratory-generated nerve cells respond to a range of different kinds of pain stimulation, including physical injury, chronic inflammation, and cancer chemotherapy.

In future they could be used to investigate the origins of pain and develop better pain-relieving drugs.

The work followed years of unsuccessful attempts to produce nerve cells from embryonic stem cells, immature blank slate cells with the potential to become any tissue in the body.

A turning point came with the development of technology that allowed ordinary skin cells to be re-programmed into induced stem cells.

A team led by Dr Clifford Woolf at Harvard Medical School used a cocktail of transcription factors proteins that control the activity of genes to transform mouse and human skin cells directly into pain-sensing neurons.

The researchers, whose findings are reported in the journal Nature Neuroscience, were able to model pain hypersensitivity experienced by patients who donated skin cells to the study.

Originally posted here:
Scientists have created 'pain in a dish'

Cambridge stem cell pioneer DefiniGEN is in China this week showcasing technology that arguably gives the UK a world lead in countering liver and pancreatic cancer.

The young company is seeking Chinese partners to broaden the reach of the technology which holds a potentially significant payback in regenerative medicine.

With US global stem cell innovator Roger Pedersen among its technology founders, DefiniGEN was founded two years ago to commercialise a stem cell production platform developed at the University of Cambridge.

The platform generates human liver and pancreatic cell types using Nobel Prize winning human Induced Pluripotent Stem Cell (iPSC) technology.

DefiniGEN is visiting Shanghai and Beijing on a trade mission organised by UKTI East of England in partnership with the China-Britain Business Council.

The company is actively looking to partner with Life Science distributors and pharmaceutical drug discovery companies in China. CEO Dr Marcus Yeo and Dr Masashi Matsunaga business development manager for Asia Pacific - are spearheading the initiative.

The visit includes a range of medically-focused ventures from one to one meetings with key players to presentations at UK consulates.

DefiniGEN cells are provided to the drug discovery sector for use in lead optimisation and toxicity programmes.

The companys OptiDIFF platform produces validated libraries of disease-modelled human liver cells for a range of diseases. The phenotype (the composite of an organisms traits) and pathology of the diseases is pre-confirmed in the cells.

The technology provides pharmaceutical companies with more predictive in vitro cell products enabling the development of safer and more effective treatments.

Original post:
Cambridge stem cell pioneer targets China partners

Contact Information

Available for logged-in reporters only

Newswise Delivering stem cell factor directly into damaged heart muscle after a heart attack may help repair and regenerate injured tissue, according to a study led by researchers from Icahn School of Medicine at Mount Sinai presented November 18 at the American Heart Association Scientific Sessions 2014 in Chicago, IL.

Our discoveries offer insight into the power of stem cells to regenerate damaged muscle after a heart attack, says lead study author Kenneth Fish, PhD, Director of the Cardiology Laboratory for Translational Research, Cardiovascular Research Center, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai.

In the study, Mount Sinai researchers administered stem cell factor (SCF) by gene transfer shortly after inducing heart attacks in pre-clinical models directly into damaged heart tissue to test its regenerative repair response. A novel SCF gene transfer delivery system induced the recruitment and expansion of adult c-Kit positive (cKit+) cardiac stem cells to injury sites that reversed heart attack damage. In addition, the gene therapy improved cardiac function, decreased heart muscle cell death, increased regeneration of heart tissue blood vessels, and reduced the formation of heart tissue scarring.

It is clear that the expression of the stem cell factor gene results in the generation of specific signals to neighboring cells in the damaged heart resulting in improved outcomes at the molecular, cellular, and organ level, says Roger J. Hajjar, MD, senior study author and Director of the Cardiovascular Research Center at Mount Sinai. Thus, while still in the early stages of investigation, there is evidence that recruiting this small group of stem cells to the heart could be the basis of novel therapies for halting the clinical deterioration in patients with advanced heart failure.

cKit+ cells are a critical cardiac cytokine, or protein receptor, that bond to stem cell factors. They naturally increase after myocardial infarction and through cell proliferation are involved in cardiac repair.

According to researchers there has been a need for the development of interventional strategies for cardiomyopathy and preventing its progression to heart failure. Heart disease is the number one cause of death in the United States, with cardiomyopathy or an enlarged heart from heart attack or poor blood supply due to clogged arteries being the most common causes of the condition. In addition, cardiomyopathy causes a loss of cardiomyocyte cells that control heartbeat, and changes in heart shape, which lead to the hearts decreased pumping efficiency.

Our study shows our SCF gene transfer strategy can mobilize a promising adult stem cell type to the damaged region of the heart to improve cardiac pumping function and reduce myocardial infarction sizes resulting in improved cardiac performance and potentially increase long-term survival and improve quality of life in patients at risk of progressing to heart failure, says Dr. Fish.

This study adds to the emerging evidence that a small population of adult stem cells can be recruited to the damaged areas of the heart and improve clinical outcomes, says Dr. Hajjar.

More here:
Delivery of Stem Cells into Heart Muscle After Heart Attack May Enhance Cardiac Repair and Reverse Injury

PUBLIC RELEASE DATE:

13-Nov-2014

Contact: Krista Conger kristac@stanford.edu 650-725-5371 Stanford University Medical Center @sumedicine

A protein that plays a critical role in preventing the development of many types of human cancers has been shown also to inhibit a vital stem cell property called pluripotency, according to a study by researchers at the Stanford University School of Medicine.

Blocking expression of the protein, called retinoblastoma, in mouse cells allowed the researchers to more easily transform them into what are known as induced pluripotent stem cells, or iPS cells. Pluripotent is a term used to describe a cell that is similar to an embryonic stem cell and can become any tissue in the body.

The study provides a direct and unexpected molecular link between cancer and stem cell science through retinoblastoma, or Rb, one of the best known of a class of proteins called tumor suppressors. Although Rb has long been known to control the rate of cell division, the researchers found that it also directly binds and inhibits the expression of genes involved in pluripotency.

"We were very surprised to see that retinoblastoma directly connects control of the cell cycle with pluripotency," said Julien Sage, PhD, associate professor of pediatrics and of genetics. "This is a completely new idea as to how retinoblastoma functions. It physically prevents the reacquisition of stem cellness and pluripotency by inhibiting gene expression."

Marius Wernig, MD, associate professor of pathology, said, "The loss of Rb appears to directly change a cell's identity. Without the protein, the cell is much more developmentally fluid and is easier to reprogram into an iPS cell."

Wernig and Sage, both members of the Stanford Cancer Institute, share senior authorship of the study, which will be published online Nov. 13 in Cell Stem Cell. Postdoctoral scholar Michael Kareta, PhD, is the lead author.

Tumor Suppressor

The rest is here:
Tumor suppressor also inhibits key property of stem cells, Stanford researchers say

Dr Saw Khay Yong Stem Cell Therapy for the Musculoskeletal System

By: Admin KLSMC

See the original post here:
Dr Saw Khay Yong Stem Cell Therapy for the Musculoskeletal System - Video

Page 1

Section: Animal Cell Technology

Enhanced cardiac differentiation of mouse embryonic stem cells by use of the slow-turning, lateral vessel (STLV) bioreactor

Sasitorn Rungarunlert Nuttha Klincumhom Istvan Bock Csilla Nemes Mongkol Techakumphu Melinda K. Pirity Andras Dinnyes

S. Rungarunlert N. Klincumhom I. Bock Cs. Nemes MK. Pirity A. Dinnyes BioTalentum Ltd., Aulich Lajos u. 26. H-2100, Godollo, Hungary

S. Rungarunlert N. Klincumhom M. Techakumphu Department of Obstetrics, Gynaecology and Reproduction, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, 10330 Thailand

I. Bock A. Dinnyes Molecular Animal Biotechnology Laboratory, Szent Istvan University, H-2100 Gdll, Hungary Corresponding author: andras.dinnyes@biotalentum.hu; Phone: +36/20/510-9632, Fax: +36/28/526-151

Emails: Sasitorn Rungarunlert nut_vs@yahoo.com Nuttha Klincumhom nuttha.klincumhom@biotalentum.hu Istvan Bock istvan.bock@biotalentum.hu Csilla Nemes csilla.nemes@biotalentum.hu Mongkol Techakumphu Mongkol.T@chula.ac.th Melinda K. Pirity melinda.pirity@biotalentum.hu

Page 2

Abstract Embryoid body (EB) formation is a common intermediate during in vitro differentiation of pluripotent stem cells into specialized cell types. We have optimized the slow-turning, lateral vessel (STLV) for large scale and homogenous EB production from mouse embryonic stem cells. The effects of inoculating different cell numbers, time of EB adherence to gelatin-coated dishes, and rotation speed for optimal EB formation and cardiac differentiation were investigated. Using 3x105 cells/ml, 10 rpm rotary speed and plating of EBs onto gelatin-coated surfaces three days after culture, were the best parameters for optimal size and EB quality on consequent cardiac differentiation. These optimized parameters enrich cardiac differentiation in ES cells when using the STLV method.

See the original post:
Enhanced cardiac differentiation of mouse embryonic stem ...

David C P. Chen, MD., MHP - Stem Cell Therapy Q A3

By: advanced anti aging center

Go here to read the rest:
David C P. Chen, MD., MHP - Stem Cell Therapy Q&A3 - Video

Contact Information

Available for logged-in reporters only

Newswise LA JOLLAResearchers at the Salk Institute have healed injured hearts of living mice by reactivating long dormant molecular machinery found in the animals cells, a finding that could help pave the way to new therapies for heart disorders in humans.

The new results, published November 6 in the journal Cell Stem Cell, suggest that although adult mammals dont normally regenerate damaged tissue, they may retain a latent ability as a holdover from development like their distant ancestors on the evolutionary tree. When the Salk researchers blocked four molecules thought to suppress these programs for regenerating organs, they saw a drastic improvement in heart regeneration and healing in the mice.

The findings provide proof-of-concept for a new type of clinical treatment in the fight against heart disease, which kills about 600,000 people each year in the United Statesmore than AIDS and all cancer types combined, according to the U.S. Centers for Disease Control and Prevention.

Organ regeneration is a fascinating phenomenon that seemingly recapitulates the processes observed during development. However, despite our current understanding of how embryogenesis and development proceeds, the mechanisms preventing regeneration in adult mammals have remained elusive, says the studys senior author Juan Carlos Izpisua Belmonte, a professor in the Gene Expression Laboratory at Salk.

Within the genomes of every cell in our bodies, we have what information we need to generate an organ. Izpisua Belmontes group has for many years focused on elucidating the key molecules involved in embryonic development as well as those potentially underlying healing responses in regenerative organisms such as the zebrafish.

Indeed, back in 2003, Izpisua Belmontes laboratory first identified the signals preceding zebrafish heart regeneration. And in a 2010 Nature paper, the researchers described how regeneration occurred in the zebrafish. Rather than stem cells invading injured heart tissue, the cardiac cells themselves were reverting to a precursor-like state (a process called dedifferentiation), which, in turn, allowed them to proliferate in tissue.

Although in theory it might have seemed like the next logical step to ask whether mammals had evolutionarily conserved any of the right molecular players for this kind of regenerative reprogramming, in practice it was a scientific risk, recalls Ignacio Sancho-Martinez, a postdoctoral researcher in Izpisua Belmontes lab.

When you speak about these things, the first thing that comes to peoples minds is that youre crazy, he says. Its a strange sounding idea, since we associate regeneration with salamanders and fish, but not mammals.

View original post here:
Salk Scientists Discover a Key to Mending Broken Hearts

PUBLIC RELEASE DATE:

6-Nov-2014

Contact: David McKeon dmckeon@nyscf.org 212-365-7440 New York Stem Cell Foundation @nyscf

New York, NY (November 6, 2014) - A team of scientists led by The New York Stem Cell Foundation (NYSCF) Research Institute successfully created a human stem cell disease model of Parkinson's disease in a dish. Studying a pair of identical (monozygotic) twins, one affected and one unaffected with Parkinson's disease, another unrelated Parkinson's patient, and four healthy control subjects, the scientists were able to observe key features of the disease in the laboratory, specifically differences in the patients' neurons' ability to produce dopamine, the molecule that is deficient in Parkinson's disease. In addition, the scientists also identified a potential strategy for developing novel therapies for Parkinson's disease.

Attributed to a combination of genetic and nongenetic factors, Parkinson's disease has no completely effective therapy or cure. Parkinson's disease is moderately heritable, but the mechanisms of this inheritance are not well understood. While genetic forms of the disease exist, sporadic forms are far more common.

"The unique scenario of identical twins, one with this disease and one without, allowed our scientists an unprecedented look into the mechanisms of Parkinson's disease," said Susan L. Solomon, NYSCF Chief Executive Officer. "Advanced stem cell research techniques allow us to push the boundaries of science and see what actually goes wrong at the cellular level, step by step during the disease process."

DNA mutations resulting in the production of a specific enzyme called glucocerebrosidase (GBA) have been linked to a five-fold greater risk of developing Parkinson's disease; however, only 30% of individuals with this mutation have been shown to develop Parkinson's disease by the age of 80. This discordance suggests that multiple factors contribute to the development of Parkinson's disease, including both genetic and non-genetic factors. To date, there has been no appropriate model to identify and test multiple triggers leading to the onset of the disease.

In this study, published today in Cell Reports, a set of identical twins, both with a GBA mutation, provided a unique opportunity to evaluate and dissect the genetic and non-genetic contributions to the development of Parkinson's disease in one twin, and the lack of disease in the other. The scientists made induced pluripotent stem (iPS) cells from skin samples from both twins to generate a cellular model of Parkinson's in a dish, recapitulating key features of the disease, specifically the accumulation of -synuclein and dopamine deficiency.

Upon analyzing the cell models, the scientists found that the dopamine-producing neurons from both twins had reduced GBA enzymatic activity, elevated -synuclein protein levels, and a reduced capacity to synthesize and release dopamine. In comparison to his unaffected brother, the neurons generated from the affected twin produced less dopamine, had higher levels of an enzyme called monoamine oxidase B (MAO-B), and poor ability to connect with each other. Treating the neurons with molecules that lowered the activity of MAO-B together with overexpressed GBA normalized -synuclein and dopamine levels in the cell models. This suggests that a combination therapy for the affected twin may be possible by simultaneously targeting these two enzymes.

"The subject of Parkinson's disease discordant twins gave us an incredible opportunity to utilize stem cell models of disease in a dish to unlock some of the biological mechanisms of disease," said Dr. Scott Noggle, NYSCF Vice President, Stem Cell Research and The NYSCF - Charles Evans Senior Research Fellow for Alzheimer's Disease. "Working with these various different groups and scientists added to the depth and value of the research and we hope our findings will be applicable to other Parkinson's disease patients and other neurodegenerative disorders."

Go here to read the rest:
Scientists create Parkinson's disease in a dish

New research from McLean Hospital and the Harvard Stem Cell Institute has shown that stem cell therapy reduces seizures in mice.

Researchers used an animal model to transplant seizure-inhibiting, human embryonic stem cell-derived neurons into the brains of mice that had a common form of epilepsy. Half of the mice that received the transplanted neurons no longer had seizures, while the other half experienced a significant drop in seizure frequency.

The transplanted neurons integrated into the mouse brains and began to receive neuronal activity. The neurons then released GABA, an inhibitory response that reversed the electrical hyperactivity that causes seizure.

Previous studies showed increasing inhibition in the epileptic brain can help control the seizure and also a lot of anti-epilepsy drugs are mimicking this GABA, so many of them worked by binding to the GABA receptor inhibitor neuron, researcher Sangmi Chung, associate professor of psychiatry at Harvard, told FoxNews.com.

Researchers initially set out to test the functionality of human neurons, but later decided to test their effect on epilepsy because it is such a devastating disease. About 30 percent of people do not respond to seizure drugs and one out of 26 people will be affected by seizures in their lifetime, Chung said.

Over 65 million people worldwide are affected by epileptic seizures, which can cause convulsions, loss of consciousness and other neurological symptoms. Patients are treated with anti-seizure drugs, and may choose to have a portion of their brain removed.

Because mouse cells mature more quickly than human cells within weeks instead of years its unclear how long a stem cell transplant in a human would take before becoming effective, Chung noted.

If we compare it with the mouse [model], we believe it will be years, not weeks, she said.

However, the study found that, even without full maturation, the cells integrated into the epileptic mouse brains, receive signals and release GABA, therefore preventing seizures.

I think its really good news in terms of transplantation even maturing, not fully mature [cells] still work, Chung said.

Read more:
Stem cell transplants may help reduce seizures, study says

16 hours ago

Researchers at the University of Cambridge have managed to reconstruct the early stage of mammalian development using embryonic stem cells, showing that a critical mass of cells not too few, but not too many is needed for the cells to being self-organising into the correct structure for an embryo to form.

All organisms develop from embryos: a cell divides generating many cells. In the early stages of this process, all cells look alike and tend to aggregate into a featureless structure, more often than not a ball. Then, the cells begin to 'specialise' into different types of cell and space out asymmetrically, forming an axis which begins to provide a structure for the embryo to develop along.

In animal embryos this stage is followed by a process known as gastrulation: a choreographed movement of the cells that, using the initial axis as a reference, positions the head and the tail, the front and the back. During the process, the cells begin to forum three distinct layers: the endoderm, mesoderm and ectoderm, determining which tissues or organs the cells will then develop into.

Professor Alfonso Martinez-Arias from the Department of Genetics at the University of Cambridge, who led the research, says: "Gastrulation was described by biologist Professor Lewis Wolpert as being 'truly the most important event in your life' because it creates the blueprint of an organism. Axis formation and gastrulation are the two central processes that initiate the development of an organism and are inextricably associated with the embryo. We have managed to recreate this for the first time in the lab."

This video is not supported by your browser at this time.

Professor Martinez-Arias and colleagues, supported by the European Research Council and the Wellcome Trust, have reconstructed these early stages of development using mouse embryonic stem cells. Embryonic stem cells, discovered in the Department of Genetics in the 1980s (for which Sir Martin Evans was awarded the Nobel Prize in Physiology or Medicine 2007), have become an important tool for developmental biology, understanding disease, and in regenerative medicine due to the ability to give rise to all cell types in culture. Over the last few years, they have been used to 'grow' organs including the eye and the cerebral cortex; surprisingly, these structures develop without an axis.

In research published today in the journal Development, the researchers report a way to coax cells to reorganize in the manner that they do in an embryo, creating an axis and undergoing movements and organisations that mimic the process of gastrulation. Over the years researchers have been making aggregates of embryonic stem cells to obtain certain cell types, for example red blood cells. However, these aggregates lack structure and the different cell types emerge in a disorganised fashion. This is the first time that researchers have been able to elicit axis formation, spatial organisation and gastrulation-like movements from aggregates of embryonic stem cells.

The researchers show that if the number of cells aggregated initially is similar to that of a mouse embryo, the cells generate a single axis and this serves as a template for a sequence of events that mimics those of the early embryo. By manipulating the signals that the cells see at a particular time, the researchers were able to influence what type of cell they become and how they are organised. In one of the experiments, for example, activation of a particular signal at the correct time elicits the appearance of the mesoderm, endoderm and ectoderm the precursors of all cell types with a spatial organization similar to that of an embryo.

Using this experimental system, the researchers were able to generate the early stages of a spinal cord, which they showed forms as part of the process of gastrulation. This finding complements previous research from the University of Edinburgh and the National Institute for Medical Research which showed that embryonic stem cells can be coaxed into this spinal cord cells; however, the Cambridge researchers showed that the in the embryo-like aggregates, the structural organization is more robust and allows for the polarised growth of the tissue.

Read the rest here:
Researchers reconstruct early stages of embryo development

Mark and Mindy Ammons lost their 2-year-old son, Christopher, in 1988 to neuroblastoma, an aggressive childhood cancer. In 2009, Mindy Ammons donated her own stem cells to a woman with cancer. And this weekend, the family's youngest son will prepare a bone marrow donor registry in memory of his oldest brother as an Eagle Scout project.

Family photo

Bone marrow donation is close to the heart for the Ammons family of Provo.

Mark and Mindy Ammons lost their 2-year-old son, Christopher, in 1988 to neuroblastoma, an aggressive childhood cancer. In 2009, Mindy Ammons donated her own stem cells to a woman with cancer. And this weekend, the familys youngest son will lead a bone marrow registry drive as an Eagle Scout project in memory of his oldest brother.

We are in the unique position of having been on both sides of the process, Mindy Ammons said.

In the "Be The Match" flier created for the project, Will Ammons, 13, explains that Christophers only chance of survival was a bone marrow transplant, but sadly, no one in our family was a match, so he had to be his own donor.

Christopher underwent treatment at the UCLA Medical Center where, after five days of chemotherapy, three days of full-body radiation and then surgery, he received his own marrow as a transplant. He died two weeks into the process, just shy of his third birthday.

Over the years, the Ammonses talked about this experience with their children and stayed informed on treatment advances. When it came time for their second oldest son, Jon, to do his Eagle Scout project, he didn't just want to do something to check off on a list. He wanted a meaningful project.

He wanted to do something that would make a difference and was cancer-related," Mindy Ammons said.

They discussed raising money for cancer research but decided that would be like dropping a coin in a well, she said.

Read the original:
Family saves lives through bone marrow registry and stem cell donation

Study Identifies Potential Treatment Target for Cocaine Addiction

30 Oct 2014A study led by investigators from Massachusetts General Hospital and the Perelman School of Medicine at the University of Pennsylvania has identified a potential target for therapies to treat cocaine addiction. Read more

27 Oct 2014A new effort mapping 24-hr patterns of expression for thousands of genes in 12 different mouse organs five years in the making provides important clues about how the role of timing may influence the way drugs work in the body. Read more

27 Oct 2014An all-female panel of luminaries in fields including epigenetics and stem cell biology will come together at a Penn symposium entitled Celebrating Women in Science. The Department of Cell and Developmental Biology at the Perelman School of Medicine, University of Pennsylvania, has organized the... Read more

22 Oct 2014A Penn Medicine-developed drug has received orphan status from the Food and Drug Administration (FDA) this month for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare, life-threatening disease that causes anemia due to destruction of red blood cells and thrombosis. Read more

22 Oct 2014Some of the most promising startup teams in healthtech will pitch their companies to an audience of several hundred investors, industry leaders and potential customers at DreamIt Health Philadelphia Demo Day on Thursday, October 30 from 9 a.m. to 2 p.m. at World Cafe Live in Philadelphia. Read more

See the original post here:
Perelman School of Medicine at the University of Pennsylvania

Adult stem cells can change the healthcare landscape

A recent Colorado political advertisement highlighting a candidates stance on stem cell research shows the issue is still at the forefront of public consciousness. Part of what makes stem cell research such a hot button issue is the number of persistent myths that propagate many of the heated emotions surrounding the topic.

Much of the stem cell controversy comes from the fact many people only know of embryonic stem cells, which are generated from fertilized, frozen eggs at in-vitro fertilization centers. These are not the only type of stem cells. Other types include umbilical cord blood and adult stem cells.

Umbilical cord blood is extracted from birth and preserved for the future benefit of the child. While this type of stem cell technique is safe and it is becoming commonplace to store the cells, there is currently no way to utilize these cells beyond compassionate care cases which are few and far between. However, adult stem cells are currently in clinical use today and are easily and safely harvested from the patients fat and bone marrow reserves. The adult stem cells can be utilized for a variety of treatment options, which include joint, ligament and tendon injuries, back pain, and autoimmune diseases.

Polls indicate a shifting paradigm in how people view stem cell use and research. A Pew Research survey conducted in 2013 revealed only 16 percent believed non-embryonic stem cell research was immoral. Pope Emeritus Benedict XVI recently gave his approval on adult stem cell research, I pray that your commitment to adult stem cell research will bring great blessings for the future of man and genuine enrichment to his culture.

Those with an understanding of adult stem cells know there is no controversy as they do not require the harming of an embryo. While progress in the realm of public opinion is being made, regulatory and administrative difficulties are still hampering medical innovation according to some healthcare experts.

Adult stem cells hold great promise for the future of medicine because of their potential to improve cartilage health, repair lumbar discs, and slow progression of autoimmune diseases. The ability to utilize stem cells from ones own body to safely and naturally heal itself from many different ailments is beginning to revolutionize healthcare.

With more public support and cooperative regulatory policies, adult stem cells have the potential to forever change the healthcare landscape as profoundly as the mark antibiotics made on medicine.

Dr. Scott Brandt

ThriveMD Aspen

Read the original post:
Letter: Adult stem cells can change the healthcare landscape

Irelands first human stem cell trial using lab-grown cells is due to get underway in Galway in the new year following approval from the medicines watchdog.

The trial will involve extracting adult mesenchymal stem cells (MSC) from the bone marrow of patients with a condition known as critical limb ischemia (CLI) a severe blockage of the arteries resulting in marked reduction in blood flow to the extremities.

Reduction in blood flow to the legs puts patients at risk of gangrene, ulceration, and amputation, and the Galway trial will look at the use of MSCs to grow new stems cells which will then be injected back into the patients leg with the hope of growing new blood cells and improving circulation.

The harvested stem cells will be grown to much greater quantities in a highly specialised lab before being injected back into the patients leg.

Tim OBrien, director of the Galway-based Regenerative Medicine Institute, said their research was focused on whether MSC therapy could improve blood flow to the legs in patients with CLI a condition common in diabetics and therefore avoid the need for amputation. The trial is aimed predominantly at testing the safety and feasibility of what is very much an experimental therapy, Prof OBrien said.

We will be doing a dose escalation study, with some patients given a small dose, others a medium dose and the remainder a high dose, he said. We want to try and establish how many cells do you need to give a patient.

The study, the first in humans in Ireland, will be a year-long study involving nine patients. Prof OBrien said they would not be advertising for participants, but rather would let clinicians know and await referrals of suitable patients.

In the meantime, they would be preparing the custom-built facility where the cells are grown, at the Centre for Cell Manufacturing Ireland in NUI Galway, the first such facility in Ireland to receive a licence from the Health Products Regulatory Authority.

Prof OBrien said MSCs have a lot of properties that may make them useful in treating a wide variety of disease because of their reparative and regenerative qualities.

Prof OBrien delivered a talk yesterday on the Therapeutic Potential of MSCs in Diabetic Complications on the second day of a two-day international stem cell conference at NUI Galway.

Continued here:
Lab-grown stem cell trial gets green light

2 hours ago A cross section through a histotripsy lesion created in bovine liver tissue with the liquified cellular contents washed out revealing the remaining extracellular matrix. The scale bar represents 5mm. Credit: T.Khoklova/UW

Researchers at the University of Washington have developed a way to use sound to create cellular scaffolding for tissue engineering, a unique approach that could help overcome one of regenerative medicine's significant obstacles. The researchers will present their technique at the 168th meeting of the Acoustical Society of America (ASA), held October 27-31, 2014, at the Indianapolis Marriott Downtown Hotel.

The development of the new technique started with somewhat of a serendipitous discovery. The University of Washington team had been studying boiling histotripsy - a technique that uses millisecond-long bursts of high-intensity ultrasound waves to break apart tissue - as a method to eliminate cancerous tumors by liquefying them with ultrasound waves. After the sound waves destroy the tumors, the body should eliminate them as cellular waste. When the researchers examined these 'decellularized' tissues, however, they were surprised by what the boiling left intact.

"In some of our experiments, we discovered that some of the stromal tissue and vasculature was being left behind," said Yak-Nam Wang, a senior engineer at the University of Washington's Applied Physics Laboratory. "So we had the idea about using this to decellularize tissues for tissue engineering and regenerative medicine."

The structure that remains after decellularizing tissues is known as the extracellular matrix, a fibrous network that provides a scaffold for cells to grow upon. Most other methods for decellularizing tissues and organs involve chemical and enzymatic treatments that can cause damage to the tissues and fibers and takes multiple days. Histrostipsy, on the other hand, offers the possibility of fast decellularization of tissue with minimal damage to the matrix.

"In tissue engineering, one of the holy grails is to develop biomimetic structures so that you can replace tissues with native tissue," Wang said. Stripping away cells from already developed tissue could provide a good candidate for these structures, since the extracellular matrix already acts as the cellular framework for tissue systems, Wang said.

Due to its bare composition, the matrix also induces only a relatively weak immune response from the host. The matrix could then theoretically be fed with stem cells or cells from the same person to effectively re-grow an organ.

"The other thought is that maybe you could just implant the extracellular matrix and then the body itself would self-seed the tissues, if it's just a small patch of tissue that you're replacing," Wang said. "You won't have any immune issues, and because you have this biomimetic scaffold that's closer to the native tissue, healing would be better, and the body would recognize it as normal tissue."

Wang is currently investigating decellularization of kidney and liver tissue from large animals. Future work involves increasing the size of the decellularized tissues and assessing their in-vivo regenerative efficacy.

Explore further: The future of regenerative medicine

View original post here:
High-intensity sound waves may aid regenerative medicine